HPD-L1 is a suspected disease in the field of blood tumours, with complex clinical performance and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of HPD-L1 requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule of disease changes.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HLPD-L1. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.